Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Beats Expectations By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA) posted its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.14, Zacks reports.

Coya Therapeutics Stock Performance

NASDAQ COYA traded down $0.11 during trading on Tuesday, hitting $6.74. 5,061 shares of the company’s stock traded hands, compared to its average volume of 73,019. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.69. The business has a 50 day moving average of $6.29 and a 200-day moving average of $6.48. The stock has a market capitalization of $112.54 million, a price-to-earnings ratio of -10.36 and a beta of 0.31.

Analyst Ratings Changes

A number of brokerages have recently issued reports on COYA. D. Boral Capital reiterated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.